Here is what you need to know on Monday, November 29:
Delta may be finally on the way out but it might be replaced by another variant as Omicron, first identified in South Africa, is now being picked up globally. Whether this is a good or bad thing is as yet unknown. Will omicron be more transmissible but milder? That would be blue-sky thinking and more study is needed. What is known is that this creates some uncertainty and as we bang on here repeatedly, markets hate uncertainty. Markets are forward-looking and can plan with known good or bad news but not with uncertainty. So we will likely see some volatility for the next few weeks until more information on omicron becomes available. Friday was an aberration with reduced holiday volumes exaggerating the fall. Already Monday is seeing a strong rally. But Merck's (MRK) anti-viral pill may not be a silver bullet so covid fears remain elevated. Friday's big winners were all the vaccine makers, with Moderna (MRNA) the standout at +20%. For now, its all hands to the holiday season as demand for the new Spiderman movie sees ticket sites crash but AMC fails to pop. Black Friday retail sales were also slightly on the low side so retail stocks could struggle. Earnings from Big Lots (BIG), Kroger (KR) and Dollar General (DG) are up this week.
The dollar meanwhile eases back from its run, to 1.1276 now against the euro, Gold is back down to $1792, bitcoin at $57,300 and Oil is back up to $71.55.
See forex today
European markets are higher: Eurostoxx +2%, FTSE +1.6% and Dax +0.7%.
US futures are higher: S&P +0.7%, Dow +0.6% and Nasdaq +0.9%.
S&P 500 (SPY) Nasdaq (QQQ) top news
AMC, Spider-Man set for big opening with ticket sites crashing, see more.
Tesla (TSLA) after last quarter's "super hardcore" Elon Musk urges focus on costs for next quarter, see more.
Moderna (MRNA) says it could have a vaccine ready for omicron variant by early 2022, see more.
Merck (MRK) data for its antiviral pill for covid not as positive as first thought. Citi downgrades.
Reuters sees online sales of $11.3 billion on cyber Monday, a drop from last year.
Phoenix Motors Co (PEV) to IPO under ticker PEV. electric vehicle company, yes another one! Rivian (RIVN) is slowing as deliveries are delayed, see more.
Pfizer (PFE) JPMorgan raises the price target.
Adagio Therapeutics (ADGI) up 30% as the company says its covid vaccine candidate is likely to be effective against omicron variant.
Hertz (HTZ) up 8% on share buyback program of $2 billion.
Li auto (LI) up 8% on earnings beat on top and bottom lines.
Upgrades and downgrades
Source: Benzinga Pro
Economic releases
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD retreats to 1.0750, eyes on Fedspeak
EUR/USD stays under modest bearish pressure and trades at around 1.0750 on Wednesday. Hawkish comments from Fed officials help the US Dollar stay resilient and don't allow the pair to stage a rebound.
GBP/USD struggles to hold above 1.2500 ahead of Thursday's BoE event
GBP/USD stays on the back foot and trades in negative territory below 1.2500 after losing nearly 0.5% on Tuesday. The renewed US Dollar strength on hawkish Fed comments weighs on the pair as market focus shifts to the BoE's policy announcements on Thursday.
Gold fluctuates in narrow range above $2,300
Gold struggles to make a decisive move in either direction and moves sideways in a narrow channel above $2,300. The benchmark 10-year US Treasury bond yield clings to modest gains near 4.5% and limits XAU/USD's upside.
SEC vs. Ripple lawsuit sees redacted filing go public, XRP dips to $0.51
Ripple (XRP) dipped to $0.51 low on Wednesday, erasing its gains from earlier this week. The Securities and Exchange Commission (SEC) filing is now public, in its redacted version.
Softer growth, cooler inflation and rate cuts remain on the horizon
Economic growth in the US appears to be in solid shape. Although real GDP growth came in well below consensus expectations, the headline miss was mostly the result of larger-than-anticipated drags from trade and inventories.